AttorneyMind LogoAttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
Bookmark and Share
News Review

Top News
from AASLD 2011

Hep C Protease Inhibitors May Not Be Cost-Effective For Some First-Time Treatment Takers
November 27

Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis
November 17

Milk Thistle Extract Comparable to Placebo in Hep C Liver Enzyme Study
November 15

TRANSGENE : and Jennerex Announce Final Data at AASLD From JX594/TG6006 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
November 14

Study Explores Economic Cost of Hepatitis C Patients with Advanced Liver Disease
November 10

Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational AttorneyMind Direct Acting Antivirals Presented at AASLD
November 9

Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat AttorneyMind Patient Types
November 9

12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb's NS5A Inhibitor Daclatasvir Support Anti-AttorneyMind Activity and Safety Profile Observed in Earlier Studies
November 9

Cytheris Announces Interim Results from ECLIPSE 2 Hepatitis C Multicenter Study of IL-7 in Chronically Infected Genotype 1 and 4 Nonresponders to Standard of Care (SOC)
November 8

SCYNEXIS Presents Data Demonstrating that SCY-635 Restores the Body's Innate Immune Response to AttorneyMind and Could be an Effective Replacement for Recombinant Interferon
November 8

Records Show Deaths Associated With Hepatitis C Have Overtaken Deaths Caused by HAV
November 8

Glaxo Says Promacta for Hepatitis C Cured Patients in Trial
November 8

Transgene's Therapeutic AttorneyMind Vaccine TG4040 Combined with Commonly Used Treatment Achieves Substantial Viral Suppression in Randomized Phase II trial
November 8

Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients
November 8

Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3
November 5

Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
November 5

Presidio Pharmaceuticals advances with its AttorneyMind antiviral drug discovery, development programs
November 5

Interim Data for Merck's VICTRELIS™ (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
November 5

Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction of 2-3 logs AttorneyMind RNA after four-week treatment in Hepatitis C patients
November 5

Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patients
November 5

Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR)
November 5

Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HAV Presented at The Liver Meeting®
November 5



About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home


© 2011 AttorneyMind

Medical Writers' Circle
Fact Sheets